Published in Proc Natl Acad Sci U S A on March 12, 2003
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA (2009) 5.75
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology (2005) 4.04
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol (2010) 3.52
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature (2006) 3.21
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
The emerging genetic architecture of type 2 diabetes. Cell Metab (2008) 2.77
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One (2009) 2.13
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci (2005) 2.03
Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol (2007) 1.90
Measures of adiposity and dementia risk in elderly persons. Arch Neurol (2007) 1.88
Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest (2006) 1.87
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol (2008) 1.82
Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci U S A (2004) 1.80
Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.78
Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci (2008) 1.73
Genomic copy number and expression variation within the C57BL/6J inbred mouse strain. Genome Res (2007) 1.71
The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci (2009) 1.62
The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm (2010) 1.59
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis (2009) 1.53
Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 1.50
BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). J Biol Chem (2011) 1.47
Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.46
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem (2005) 1.44
Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J (2004) 1.43
Mild cognitive impairment and dementia: the importance of modifiable risk factors. Dtsch Arztebl Int (2011) 1.43
Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis (2009) 1.42
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet? PLoS One (2011) 1.39
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics (2008) 1.36
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ (2004) 1.36
Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One (2010) 1.35
beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol (2006) 1.35
Neuropsychological contributions to the early identification of Alzheimer's disease. Neuropsychol Rev (2008) 1.35
BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol (2005) 1.34
ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? Neuron (2014) 1.33
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Insulin receptor signaling in the development of neuronal structure and function. Neural Dev (2010) 1.29
Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis (2012) 1.28
Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol (2007) 1.28
Evidence of a role for lactadherin in Alzheimer's disease. Am J Pathol (2007) 1.28
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 1.28
Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem (2010) 1.28
Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol Biol Cell (2006) 1.26
Mechanisms of insulin resistance in obesity. Front Med (2013) 1.26
Retracted Environmental experience modulates ischemia-induced amyloidogenesis and enhances functional recovery. J Neurotrauma (2009) 1.25
Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J Neurochem (2008) 1.23
Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis (2008) 1.23
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Amyloid-β as a modulator of synaptic plasticity. J Alzheimers Dis (2010) 1.22
Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem (2009) 1.20
High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One (2013) 1.20
A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc Natl Acad Sci U S A (2004) 1.18
Insulin action in brain regulates systemic metabolism and brain function. Diabetes (2014) 1.18
Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. J Mol Biol (2009) 1.17
Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature (2014) 1.17
Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care (2009) 1.17
The AbetaCs of Abeta-cleaving proteases. J Biol Chem (2008) 1.16
Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J (2010) 1.16
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis (2007) 1.13
Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. PLoS One (2011) 1.11
Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis (2010) 1.10
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Abeta aggregation and possible implications in Alzheimer's disease pathogenesis. J Cell Mol Med (2009) 1.09
Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex (2013) 1.09
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. PLoS One (2010) 1.07
Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. J Alzheimers Dis (2010) 1.07
Insulin, cognition, and dementia. Eur J Pharmacol (2013) 1.06
Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc Natl Acad Sci U S A (2008) 1.06
Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J Biol Chem (2009) 1.04
Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO J (2007) 1.04
Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One (2009) 1.03
Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol (2010) 1.02
The dynamics of monocytes and microglia in Alzheimer's disease. Alzheimers Res Ther (2015) 1.02
Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One (2010) 1.02
Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem (2011) 1.02
Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes (2014) 1.01
Decreased proteolytic activity of the mitochondrial amyloid-β degrading enzyme, PreP peptidasome, in Alzheimer's disease brain mitochondria. J Alzheimers Dis (2011) 1.01
Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta (2008) 1.01
Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord (2010) 1.01
Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem (2009) 1.00
The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of α-synuclein levels in β-cells. Diabetes (2013) 1.00
Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin. Mol Biol Cell (2007) 0.99
Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement (2014) 0.99
Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother (2010) 0.99
Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 0.99
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener (2011) 0.99
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) (2014) 0.98
Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res (2015) 0.98
Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care (2010) 0.98
Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener (2012) 0.98
Actions of β-amyloid protein on human neurons are expressed through the amylin receptor. Am J Pathol (2010) 0.97
Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol (1982) 14.41
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 7.55
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science (2001) 7.03
Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature (1998) 6.82
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell (2002) 5.15
Metabolic regulation of brain Abeta by neprilysin. Science (2001) 4.47
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest (1997) 3.66
Insulin degradation: progress and potential. Endocr Rev (1998) 3.57
beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell (1995) 3.33
A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet (2001) 3.26
Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet (2000) 3.17
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science (2000) 3.16
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol (1997) 2.60
Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem Biophys Res Commun (1997) 2.55
The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet (2000) 2.50
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem (2001) 2.42
Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science (2000) 2.35
Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci (2000) 2.22
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes (2002) 1.99
The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia (2001) 1.99
Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol Dis (1997) 1.92
Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem (2002) 1.87
Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging (1996) 1.80
Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci (2001) 1.75
The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J Neurochem (2001) 1.73
A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes (2000) 1.73
Neutral endopeptidase modulation of septic shock. J Exp Med (1995) 1.53
Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci (1998) 1.50
Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol (1998) 1.49
Degradation of amylin by insulin-degrading enzyme. J Biol Chem (2000) 1.48
Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J Biol Chem (2002) 1.45
Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem (1997) 1.43
Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. Am J Pathol (1991) 1.43
Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care (1997) 1.39
Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation. Proc Natl Acad Sci U S A (2000) 1.30
Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci (2000) 1.27
Insulin-degrading enzyme. Clin Invest Med (1996) 1.26
Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology (1999) 1.24
Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry (2002) 1.13
Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp Gerontol (2000) 1.11
Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum Genet (2001) 1.08
Hyperinsulinaemia and Alzheimer's disease. Age Ageing (1994) 1.07
Insulin and glucagon degradation by the same enzyme. Diabetes (1974) 1.03
The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. J Biol Chem (1990) 1.02
Confirmation of association between D10S583 and Alzheimer's disease in a case--control sample. Neurosci Lett (2002) 1.01
Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry (1991) 1.01
Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity. Diabetes (1984) 1.00
Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci Lett (2002) 1.00
Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans? Metabolism (2001) 0.84
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med (2012) 6.27
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
The genetics of Alzheimer disease: back to the future. Neuron (2010) 4.91
Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron (2004) 4.88
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci (2008) 4.64
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci (2010) 4.25
Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci (2006) 4.14
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. N Engl J Med (2007) 3.71
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A (2003) 3.36
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet (2003) 3.00
Alzheimer's disease: the cholesterol connection. Nat Neurosci (2003) 2.99
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis (2006) 2.96
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med (2012) 2.77
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 27-2004. A 79-year-old woman with disturbances in gait, cognition, and autonomic function. N Engl J Med (2004) 2.67
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci (2005) 2.57
The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol (2008) 2.54
A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci (2007) 2.48
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron (2003) 2.43
The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci (2007) 2.42
Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry (2009) 2.38
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology (2006) 2.26
The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci (2007) 2.25
The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem (2003) 2.22
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
Purification and characterization of the human gamma-secretase complex. Biochemistry (2004) 2.18
Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett (2004) 2.16
Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A (2002) 2.16
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest (2011) 2.08
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol (2009) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The genetic epidemiology of neurodegenerative disease. J Clin Invest (2005) 2.08
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A (2007) 2.05
Posterior circulation stroke after C1-C2 intraarticular facet steroid injection: evidence for diffuse microvascular injury. Anesthesiology (2010) 2.04
Detection of entorhinal layer II using 7Tesla [corrected] magnetic resonance imaging. Ann Neurol (2005) 2.02
Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A (2003) 2.02
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem (2008) 2.00
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Case records of the Massachusetts General Hospital. Case 9-2015. A 31-year-old man with personality changes and progressive neurologic decline. N Engl J Med (2015) 1.97
Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol (2004) 1.95
Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem (2007) 1.95
The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J Neurochem (2011) 1.93
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91